Aravive, Inc. (ARAV): Price and Financial Metrics


Aravive, Inc. (ARAV): $1.73

-0.06 (-3.35%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ARAV to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ARAV POWR Grades

  • Sentiment is the dimension where ARAV ranks best; there it ranks ahead of 95.43% of US stocks.
  • ARAV's strongest trending metric is Quality; it's been moving up over the last 56 days.
  • ARAV's current lowest rank is in the Momentum metric (where it is better than 5.13% of US stocks).

ARAV Stock Summary

  • Of note is the ratio of ARAVIVE INC's sales and general administrative expense to its total operating expenses; merely 6.27% of US stocks have a lower such ratio.
  • With a year-over-year growth in debt of -33.34%, ARAVIVE INC's debt growth rate surpasses just 9.44% of about US stocks.
  • Revenue growth over the past 12 months for ARAVIVE INC comes in at -28.78%, a number that bests just 6.53% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to ARAVIVE INC, a group of peers worth examining would be IVA, FSR, CKPT, HGEN, and GOVX.
  • Visit ARAV's SEC page to see the company's official filings. To visit the company's web site, go to aravive.com.

ARAV Valuation Summary

  • ARAV's price/sales ratio is 12; this is 135.29% higher than that of the median Healthcare stock.
  • Over the past 108 months, ARAV's price/earnings ratio has gone up 37.7.

Below are key valuation metrics over time for ARAV.

Stock Date P/S P/B P/E EV/EBIT
ARAV 2023-01-20 12.0 6.9 -1.7 -1.3
ARAV 2023-01-19 11.6 6.7 -1.7 -1.2
ARAV 2023-01-18 11.6 6.6 -1.7 -1.2
ARAV 2023-01-17 11.9 6.8 -1.7 -1.3
ARAV 2023-01-13 12.4 7.1 -1.8 -1.4
ARAV 2023-01-12 12.3 7.1 -1.8 -1.3

ARAV Growth Metrics

    Its year over year price growth rate is now at -76.86%.
  • Its 4 year net cashflow from operations growth rate is now at 62.9%.
  • Its 2 year net income to common stockholders growth rate is now at -81.83%.
Over the past 67 months, ARAV's revenue has gone up $8,648,000.

The table below shows ARAV's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 8.648 -59.186 -60.153
2022-06-30 6.104 -48.917 -55.576
2022-03-31 8.278 -35.048 -44.204
2021-12-31 7.442 -32.177 -39.151
2021-09-30 12.142 -19.61 -30.241
2021-06-30 9.73 -17.244 -29.815

ARAV's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ARAV has a Quality Grade of C, ranking ahead of 49.15% of graded US stocks.
  • ARAV's asset turnover comes in at 0.129 -- ranking 240th of 680 Pharmaceutical Products stocks.
  • ASLN, BPTH, and XBIO are the stocks whose asset turnover ratios are most correlated with ARAV.

The table below shows ARAV's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.129 1 -5.812
2021-03-31 0.083 1 -3.701
2020-12-31 0.084 1 -3.246
2020-09-30 0.000 NA -2.303
2020-06-30 0.000 NA -1.625
2020-03-31 0.043 1 -1.306

ARAV Price Target

For more insight on analysts targets of ARAV, see our ARAV price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $22.00 Average Broker Recommendation 1.3 (Strong Buy)

ARAV Stock Price Chart Interactive Chart >

Price chart for ARAV

ARAV Price/Volume Stats

Current price $1.73 52-week high $2.40
Prev. close $1.79 52-week low $0.58
Day low $1.68 Volume 25,390
Day high $1.79 Avg. volume 102,386
50-day MA $1.52 Dividend yield N/A
200-day MA $1.17 Market Cap 103.50M

Aravive, Inc. (ARAV) Company Bio


Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, triple negative breast cancer, acute myeloid leukemia, and pancreatic cancer. The company has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.


ARAV Latest News Stream


Event/Time News Detail
Loading, please wait...

ARAV Latest Social Stream


Loading social stream, please wait...

View Full ARAV Social Stream

Latest ARAV News From Around the Web

Below are the latest news stories about ARAVIVE INC that investors may wish to consider to help them evaluate ARAV as an investment opportunity.

Aravive Announces Fast Track Designation of Batiraxcept for Treatment of ccRCC

FDA decision based on new Phase 1b data: Objective Response Rate (ORR) of 57% and median Progression-Free Survival (PFS) of 11.4 months in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have progressed after 1 or 2 prior lines of immuno-oncology (IO)- and vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI)-based therapiesHOUSTON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology comp

Yahoo | November 29, 2022

Aravive To Participate in Piper’s 34th Annual Healthcare Conference

HOUSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and Rudy Howard, Chief Financial Officer will be presenting a corporate overview and participating in 1x1 meetings at the Piper 34th Annual Healthcare Conference being held on November 29 – December 1, 2022 in New York, NY. Piper 34th Annual Healthcare

Yahoo | November 21, 2022

Aravive Regains Compliance with Nasdaq Minimum Bid Price Requirement

HOUSTON, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the receipt of a formal notification from the Staff at The Nasdaq Stock Market, LLC (“Nasdaq”) on November 10, 2022 that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1). The Company was previously notified by the Staff at Na

Yahoo | November 16, 2022

H.C. Wainwright Sticks to Their Buy Rating for Aravive (ARAV)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Aravive (ARAV - Research Report) today and set a price target of $7.00. The company's shares opened today at $1.40.According to TipRanks, Pantginis is an analyst with an average return of -19.7% and a 26.95% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Decibel Therapeutics, and Biomea Fusion.Aravive has an analyst consensus of Strong Buy, with a price target consensus of $9.67, which is a 590.71% upside from current levels. In a report released on October 27, Roth Capital also maintained a Buy rating on the stock with a $10.00 price target.

Jason Carr on TipRanks | November 10, 2022

Aravive (ARAV) Reports Q3 Loss, Tops Revenue Estimates

Aravive (ARAV) delivered earnings and revenue surprises of 20.31% and 298.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 10, 2022

Read More 'ARAV' Stories Here

ARAV Price Returns

1-mo 31.06%
3-mo 1.17%
6-mo 100.05%
1-year -15.20%
3-year -82.70%
5-year -85.58%
YTD 31.06%
2022 -39.73%
2021 -61.17%
2020 -58.74%
2019 288.35%
2018 -73.33%

Continue Researching ARAV

Want to see what other sources are saying about Aravive Inc's financials and stock price? Try the links below:

Aravive Inc (ARAV) Stock Price | Nasdaq
Aravive Inc (ARAV) Stock Quote, History and News - Yahoo Finance
Aravive Inc (ARAV) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8017 seconds.